Evaluation of Anticancer Activity of Boswellic Acid and Montelukast Sodium against Human Prostate Cancer Cell Line PC-3 Anticancer activity of Boswellic Acid and Montelukast Sodium
Iranian Journal of Pharmaceutical Sciences,
مجلد 12 عدد 4 (2016),
1 October 2016
,
الصفحة 15-32
https://doi.org/10.22037/ijps.v12.40710
الملخص
Prostate cancer is a devastating disease for which current therapies are inadequate. Various lines of evidences have suggested the 5-lipoxygenase (5-LOX) pathway and the leukotriene receptor pathway are potential targets for prevention or treatment of Prostate cancer. Thus, search for new anti-cancer drugs targeting 5-LOX and leukotriene is very essential and important. The objective of the present study was to evaluate the in vitro anti- cancer effects of 5-LOX inhibitor-Boswellic acid and cysteinyl leukotrienes receptor antagonist-Montelukast sodium by 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) assay and Sulphorodamine B assay (SRB) against human prostate cancer cell line PC-3. Cell viability was assayed by trypan blue dye exclusion assay. A study was carried out in 24, 48, and 72 hours. In addition, effect of combination of both the above drugs was also determined by the same assays. Boswellic acid and Montelukast sodium demonstrated a substantial anti-cancer effect against the PC-3 cell line. The cytotoxicity of both the drugs increased with increase in duration of drug treatment. A combination of both drugs showed significant reduction in cell viability but did not show any synergistic activity. Complete dose-response curves were generated and IC50 values were calculated for all the assays. IC50 Value for Boswellic acid was found to be 49.15- 45.80 μg/ml and 50.14-43.39 μg/ml by MTT assay and SRB assay, respectively at the same time IC50 value for Montelukast sodium was 49.27-46.77 μg/ml and 46.68-46.47 μg/ml by MTT assay and SRB assay respectively. In summary, Boswellic acid and Montelukast sodium are likely to be valuable for the treatment of prostate cancer, but further studies are required for their more extensive biological evaluations.
- Anti-cancer activity
- Boswellic Acid
- Montelukast Sodium
- MTT assay
- PC-3 cell line
- SRB assay
كيفية الاقتباس
المراجع
[2] Coussens LM, and Werb Z. Inflammation and cancer. Nature. (2002) 420: 860–867.
[3] Fleshner N, Bagnell PS, Klotz L, Venkateswaran V. Dietary fat and prostate cancer. J. Urol. (2004) 171:19–24.
[4] Kolonel LN, Nomura AN, Cooney RV. Dietary fat and prostate cancer: current status. J. Natl. Cancer Inst. (1999) 91:414–428.
[5] West DW, Slattery ML, Robison LM, French TK, Mahoney AW. Adult dietary intake and prostate cancer risk in Utah: a case control study with special emphasis on aggressive tumors. Cancer Causes Control. (1991) 2:85–94.
[6] Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG and Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer. (2001) 91: 737–743.
[7] Bishayee K & Khuda-Bukhsh AR. 5-Lipoxygenase Antagonist therapy: a new approach towards targeted cancer chemotherapy. Acta Biochim Biophys Sin. (2013) xx: 1–11
[8] Hassan S and Carraway RE. Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth. Regul Pept. (2006) 133(1-3): 105-14.
[9] Ghosh J and Myers CE. Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv. Exp. Med. Biol. (1999) 469: 577–582.
[10] Ding XZ, Kuszynski CA, El-Metwally TH and Adrian TE. Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochemical and Biophysical Research Communications.(1999) 266(2): 392–399.
[11] Tong WG, Ding XZ, Witt RC and Adrian TE. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Molecular Cancer Therapeutics. (2002) 1(11): 929–935.
[12] Catalano A, Rodilossi S, Caprari P, Coppola V and Procopio A. 5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation. EMBO J. (2004) 24: 170-179.
[13] Kanaoka Y and Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol. (2004) 173: 1503–1510.
[14] Matsuyama M and Yoshimura R. Cysteinyl-leukotriene1 receptor is a potent target for the prevention and treatment of human urological cancer. Mol Med Rep (2010) 3: 245-251.
[15] Nozaki M, Yoshikawa M, Ishitani K, Kobayashi H, Houkin K, Imai K, Ito Y and Muraki T. Cysteinyl Leukotriene Receptor Antagonists Inhibit Tumor Metastasis by Inhibiting Capillary Permeability. Keio J Med.( 2010) 59(1): 10–18.
[16] Shah BA, Qazi GN and Taneja SC. Boswellic acids: a group of medicinally important compounds. Nat. Prod. Rep. (2009) 26: 72–89.
[17] Moussaieff A and Mechoulam R. Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J. Pharm. Pharmacol. (2009) 61: 1281–1293.
[18] Glaser T, Winter S, Groscurth P, Safayhi H, Sailer ER, Ammon HP, Schabet M and Weller M. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br. J. Cancer. (1999) 80: 756–765.
[19] Liu JJ, Haung B and Hooi SC. Acetyl-keto-beta-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells. Br. J. Pharmacol., (2006) 148: 1099–1107.
[20] Hostanska K, Daum G and Saller R. Cytostatic and apoptosis-inducing activity of boswellic acids toward malignant cell lines in vitro
[21] . Anticancer Res. (2002) 22: 2853–2862.
[22] Yadav VR, Prasad S, Sung B, Gelovani JG, Guha S, Krishnan S and Aggarwal BB. Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive, and angiogenic biomarkers. Int.J. Cancer. (2012) 130: 2176–2184.
[23] Park B, Sung B, Yadav VR, Cho SG, Liu M and Aggarwal BB. Acetyl-11-keto-β-boswellic acid suppresses invasion of pancreatic cancer cells through the downregulation of CXCR4 chemokine receptor expression. Int. J. Cancer. (2011) 129: 23–33.
[24] Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. (1983) 65(1-2): 55-63.
[25] Yousefi M, Safari M, Torbati MB and Amanzadeh A. In vitro anti-proliferative activity of novel hexacoordinated triphenyltin (IV) Trifluoroacetate containing a bidentate n-donor ligand. Journal of Structural Chemistry. (2014) 55(1): 101-106.
[26] Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxic assay for anticancer drug screening. J Natl Cancer Inst. (1990) 82:1107-1112.
[27] Nie D, Che M, Grignon D, Tang K, Honn KV, Role of eicosanoids in prostate cancer progression. Cancer metastasis rev. (2001) 20: 195-206.
[28] Zaslau S, Sparks S, Riggs D, Jackson B and Kandzari S. Pentosan polysulfate (Elmiron): in vitro effects on prostate cancer cells regarding cell growth and vascular endothelial growth factor production. The American Journal of Surgery. (2006) 192(5): 640-643.
[29] Ghosh J and Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA. (1998) 95(22): 13182-13187.
[30] Anderson KM, Seed T, Vos M, Mulshine J,
[31] Meng J, Alrefai W, Ou D and Harris JE. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate. (1998) 37: 161–173.
[32] Matsuyama M, Hayama T, Funao K, Kawahito Y, Sano H, Takemoto Y, Nakatani T, Yoshimura R. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncol Rep. (2007) 18: 99-104
[33] Sveinbjörnsson B, Rasmuson A, Baryawno N, Wan M, Pettersen I, Ponthan F, Orrego A, Haeggström JZ, Johnsen JI, Kogner P. Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy. FASEB J. (2008) 22: 3525-3536
- الملخص المشاهدات: 108 الأوقات
- IJPS_Volume 12_Issue 4_Pages 15-32 (English) التنزيلات: 49 الأوقات